LRRK2 and Parkinson disease: Inhibitors of LRRK2 activity (either pharmacological kinase inhibitors or anti-sense oligonucleotides that decrease LRRK2 expression) demonstrate promising results in pre-clinical and early phase clinical studies for PD.